國家衛生研究院 NHRI:Item 3990099045/15719
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 910695      線上人數 : 865
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/15719


    題名: Use of leukotriene-receptor antagonists and risk of neuropsychiatric adverse events: A nationwide population-based cohort study
    作者: Kao, HF;Tsai, HJ;Chang, YC;Tsai, YF;Yao, TC
    貢獻者: Institute of Population Health Sciences
    摘要: Background: Leukotriene-receptor antagonists (LTRA) are a class of remedies commonlyused for treating patients with asthma and/or allergic rhinitis. However, the evidence aboutthe association between LTRA use and neuropsychiatric adverse events from observationalstudies has been inconclusive. Most results are based on pediatric populations, little is knownin relation to potential neuropsychiatric adverse events among adults, especially Asianpopulations. Method: We used medical claims data derived from the entire National Health InsuranceResearch Database in Taiwan to identify study patients during 2008 and 2018. Exposure wasdefined as patients having at least 1 dispensed prescription for LTRA after asthma diagnosisduring study period. Inverse probability of treatment weighting using propensity score wasapplied to control for the systematic differences at baseline between LTRA users and non-users. Main outcomes are primary diagnoses of neuropsychiatric adverse events (psychoticdisorder, mood disorder, anxiety disorder, sleep-related disorder, cognitive disorder,movement disorder, and personality disorder) during the subsequent 12 months afterinitiation. Cox proportional hazards models with covariate adjustment were performed todetermine the associations between LTRA exposure and neuropsychiatric adverse events. Results: A total of 1,010,556 patients with asthma (222,075 LTRA users and 788,481 non-users) was identified in the study cohort. The results suggest positive significant associationsof LTRA exposure with psychotic disorder and movement disorder among study patients(adjusted hazard ratio (AHR) = 1.59; 95% confidence interval (CI): 1.07-2.36 for psychoticdisorder and AHR = 1.34; 95% CI: 1.01-1.77 for movement disorder). Conclusion: This study suggests that LTRA use is associated with increased risk ofneuropsychiatric adverse events, specifically psychotic disorder and movement disorder,during the subsequent 12 months after LTRA initiation. Our findings suggest that cliniciansadministering LTRA to patients with asthma should monitor potential neuropsychiatricadverse events during LTRA treatment.
    日期: 2023-12
    關聯: Allergy. 2023 Dec;78(Suppl. 112):471.
    Link to: http://dx.doi.org/10.1111/all.15925
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0105-4538&DestApp=IC2JCR
    顯示於類別:[蔡慧如] 會議論文/會議摘要

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ISI001144363000365.pdf369KbAdobe PDF48檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋